Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Advanced Solid Tumor Cancers|Medulloblastoma|Basal Cell Carcinoma
DRUG: LDE225
determine maximum tolerated dose of single agent LDE225, 28 day cycles
characterize safety and tolerability, 28 day cycles|characterize pharmacokinetics (PK) of single and repeated doses of LDE225, 28 day cycles|assess preliminary anti-tumor activity, every other 28-day cycle
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.